ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
HKSE: 1541.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Wenzhi Tian
- Employees
- 156
- Headquarters
- Shanghai, China
- IPO year
- 2023
- Market cap
- HK$1.8B
- Website
- https://www.immuneonco.com
Loading 1541…
Loading profile data…Frequently asked questions about 1541
What does ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) do?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin...
Where does 1541.HK trade?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) trades on the Hong Kong Stock Exchange.
What sector is 1541.HK in?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.?
Wenzhi Tian is the chief executive officer of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK).
Where is ImmuneOnco Biopharmaceuticals (Shanghai) Inc. headquartered?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is headquartered in China.
Does 1541.HK pay a dividend?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1541.HK go public?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) completed its initial public offering in 2023.